## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($310.09)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. What Amgen (AMGN)'s Expanded UPLIZNA Approval in Generalized Myasthenia Gravis Means For Shareholders**
- Source: Simply Wall Street | 20251216T052453 | Bullish | Relevance: 100%
- Amgen recently received FDA approval for an expanded label for UPLIZNA, now including adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive. This approval strengthens Amgen's position in rare autoimmune diseases, offering a differentiated b-cell therapy with low-frequency dosing. While this expands Amgen's rare-disease reach, the company still faces challenges from biosimilar erosion and drug pricing pressures, though a recent dividend increase signals management's confidence in cash flow durability.

**2. Assessing Amgen (AMGN)’s Valuation After FDA Approval of Uplizna for Generalized Myasthenia Gravis**
- Source: Simply Wall Street | 20251213T140721 | Bullish | Relevance: 100%
- Amgen (AMGN) recently secured FDA approval for Uplizna, its CD19 targeted B cell therapy for generalized myasthenia gravis, leading to a reassessment of its valuation. Despite strong year-to-date share price performance and a recent dividend increase, the article asks if Amgen is undervalued given its expanding rare disease portfolio or if future growth is already priced in. A narrative valuation suggests the stock is modestly undervalued with a fair value of $322.88 based on projected revenues and earnings by 2028.

**3. Assessing Amgen (AMGN)’s Valuation After FDA Approval of Uplizna for Generalized Myasthenia Gravis**
- Source: Simply Wall Street | 20251213T143541 | Bullish | Relevance: 100%
- Amgen (AMGN) recently received FDA approval for Uplizna, a CD19 targeted B cell therapy for generalized myasthenia gravis, leading to a reassessment of its long-term growth prospects. The stock has seen a robust year-to-date return of approximately 22% and a one-year total shareholder return of over 21%, currently trading around $317.74. While analysts project a fair value of $322.88, indicating it is slightly undervalued, this depends on the company's ability to navigate biosimilar pressure and drug price reform.

**4. Amgen (AMGN) Rises As Market Takes a Dip: Key Facts**
- Source: Yahoo Finance Singapore | 20251215T230811 | Somewhat-Bullish | Relevance: 100%
- Amgen (AMGN) shares rose by 2.38% despite a broader market dip, with the S&P 500 and Dow experiencing losses. Upcoming financial results project a decrease in EPS but an increase in revenue for Amgen, with analysts showing optimism for future profitability. The company currently holds a Zacks Rank of #3 (Hold) and is valued at a discount compared to its industry average.

**5. Amgen Inc. $AMGN Position Lowered by Texas Permanent School Fund Corp**
- Source: MarketBeat | 20251215T131552 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp reduced its stake in Amgen Inc. by 31.6% in the second quarter, now holding 42,190 shares valued at $11.78 million. This comes as Amgen reported strong quarterly earnings, beating analyst expectations with $5.64 EPS on $9.56 billion in revenue, and raised its quarterly dividend to $2.52 per share. Other institutional investors showed mixed activity, with some increasing and others decreasing their holdings in the medical research company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Forward P/E 14.8x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $175.2B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 14.8 |
| Current P/E | 15.3 |
| YoY Growth | 3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -8.7% to -2.1% (+6.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.1pp (needs >4.0% for momentum thesis). MRS_5 turning positive (3.9%) - potential reversal signal. Underperforming sector by 3.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-3.54), momentum weakening. RSI neutral at 50. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.11% (CS: 20) | Weak |
| RSI_14 | 50.1 | Neutral |
| MACD Histogram | -3.54 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 1.030x | Above |
| vs SMA200 | 1.095x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $325.31
- **Stop Loss:** $310.09 (4.7% risk)
- **Target:** $355.75 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 78
- **Position Value:** $25,374.18
- **Portfolio %:** 25.37%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*